New data for KSI-101 from the APEX study reinforce its clinically meaningful vision gains and rapid retinal drying in macular edema secondary to inflammation (MESI)
Extended Durability in Exudative Retinal Diseases Using the Novel Intravitreal Anti-VEGF Antibody Biopolymer Conjugate KSI-301 (10-month Data from Phase 1b Study in Patients with wAMD, DME and RVO)
By
X
1250 Page Mill Road Palo Alto, CA 94304 United States of America